Fundz

Palvella Therapeutics Appoints David W. Osborne, Ph.D. as Chief Innovation Officer

PRIVATESep 03, 2025

Position

Chief Innovation Officer

Company

Palvella Therapeutics

David W. Osborne
WayneBiotechnology

Description

Palvella Therapeutics has announced the appointment of David W. Osborne, Ph.D. as Chief Innovation Officer

Who to call at Palvella Therapeutics, and when

A new leader at Palvella Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Palvella Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Palvella Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Palvella Therapeutics

Location

125 STRAFFORD AVENUE

Wayne, Pennsylvania, United States

About

Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Palvella Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Palvella Therapeutics's next move

Learn about Strategic plan

Palvella Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.